{
    "nctId": "NCT00045097",
    "briefTitle": "Ixabepilone in Treating Patients With Locally Advanced or Metastatic Breast Cancer",
    "officialTitle": "A Phase II Clinical Trial Of BMS-247550 (NSC 710428), An Epothilone B Analog, In Patients With Breast Carcinoma",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "N/A",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": "N/A",
    "primaryOutcomeMeasure": "Anti-tumor activity as measured by CT scans and bone scans at baseline and every other course",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed\\* adenocarcinoma of the breast\n\n  * Incurable, locally advanced or metastatic disease\n  * Primarily stage IV disease, but some inoperable stage III disease may be eligible (e.g., a patient with T4 and/or N2-3 disease who cannot receive doxorubicin or who has already received other therapy) NOTE: \\*Patients with no available tissue for histologic confirmation but who have documentation of breast surgery and prior chemotherapy are eligible upon approval of the principal investigator\n* Measurable disease\n* No evidence of CNS metastases by brain MRI or contrast head CT scan\n\n  * CNS metastases controlled by radiotherapy or surgical resection at least 6 months prior to study enrollment are allowed\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over\n\nSex\n\n* Female or male\n\nMenopausal status\n\n* Not specified\n\nPerformance status\n\n* ECOG 0-2\n\nLife expectancy\n\n* At least 3 months\n\nHematopoietic\n\n* Granulocyte count at least 1,200/mm\\^3\n* Platelet count at least 100,000/mm\\^3\n\nHepatic\n\n* Bilirubin no greater than 1.5 times upper limit of normal (ULN) (3 times ULN if there is clinical evidence of Gilbert's disease)\n* AST and ALT no greater than 2.5 times ULN\n\nRenal\n\n* Creatinine normal OR\n* Creatinine clearance greater than 40 mL/min\n\nOther\n\n* No poor medical risk due to other nonmalignant systemic disease\n* No active uncontrolled infection\n* No sensory, motor, or cranial neuropathy or neuropathic pain grade 2 or greater (unless neuropathy is clearly due to underlying breast cancer)\n* No other concurrent serious medical illness\n* No prior severe hypersensitivity reactions to agents containing Cremophor EL\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception during and for 2 months after study participation\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* More than 4 weeks since prior filgrastim (G-CSF), pegfilgrastim, or thrombopoietin (or other platelet growth factors)\n* No concurrent immunotherapy\n\nChemotherapy\n\n* More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)\n* No other concurrent chemotherapy for breast cancer\n\nEndocrine therapy\n\n* More than 2 weeks since prior hormonal therapy\n* No concurrent hormonal therapy\n\nRadiotherapy\n\n* See Disease Characteristics\n* No prior craniospinal radiation\n* No prior total body irradiation\n* More than 4 weeks since prior radiotherapy\n\nSurgery\n\n* See Disease Characteristics\n\nOther\n\n* No other concurrent investigational drugs\n* No concurrent cytochrome p450 3A4 inhibitors, including any of the following:\n\n  * Clarithromycin\n  * Erythromycin\n  * Troleandomycin\n  * Delaviridine\n  * Nelfinavir\n  * Amprenavir\n  * Ritonavir\n  * Indinavir\n  * Saquinavir\n  * Lopinavir\n  * Itraconazole\n  * Ketoconazole\n  * Fluconazole (\\> 200 mg/day)\n  * Voriconazole\n  * Nefazodone\n  * Fluvoxamine\n  * Verapamil\n  * Diltiazem\n  * Amiodarone\n* Concurrent bisphosphonates for bone metastases allowed",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}